Microenvironment-Responsive Hydrogel Reduces Seizures After Traumatic Brain Injury in Juvenile Rats by Reducing Oxidative Stress and Hippocampal Inflammation
- PMID: 38810210
- DOI: 10.1002/mabi.202400050
Microenvironment-Responsive Hydrogel Reduces Seizures After Traumatic Brain Injury in Juvenile Rats by Reducing Oxidative Stress and Hippocampal Inflammation
Abstract
Traumatic brain injury (TBI) is the primary cause of child mortality and disability worldwide. It can result in severe complications that significantly impact children's quality of life, including post-traumatic epilepsy (PTE). An increasing number of studies suggest that TBI-induced oxidative stress and neuroinflammatory sequelae (especially, inflammation in the hippocampus region) may lead to the development of PTE. Due to the blood-brain barrier (BBB), typical systemic pharmacological therapy for TBI cannot deliver berberine (BBR) to the targeted location in the early stages of the injury, although BBR has strong anti-inflammatory properties. To break through this limitation, a microenvironment-responsive gelatin methacrylate (GM) hydrogel to deliver poly(propylene sulfide)60 (PPS60) and BBR (GM/PB) is developed for regulating neuroinflammatory reactions and removing reactive oxygen species (ROS) in the brain trauma microenvironment through PPS60. In situ injection of the GM/PB hydrogel efficiently bypasses the BBB and is administered directly to the surface of brain tissue. In post-traumatic brain injury models, GM/PB has the potential to mitigate oxidative stress and neuroinflammatory responses, facilitate functional recovery, and lessen seizing. These findings can lead to a new treatment for brain injuries, which minimizes complications and improves the quality of life.
Keywords: epilepsy; microenvironment‐responsive hydrogel; neuroinflammation; reactive oxygen species; traumatic brain injury.
© 2024 Wiley‐VCH GmbH.
Similar articles
-
Responsive nanoparticles synergize with Curcumin to break the "reactive oxygen Species-Neuroinflammation" vicious cycle, enhancing traumatic brain injury outcomes.J Nanobiotechnology. 2025 Mar 5;23(1):172. doi: 10.1186/s12951-025-03251-y. J Nanobiotechnology. 2025. PMID: 40045354 Free PMC article.
-
Acute Treatment with Fucoidan Ameliorates Traumatic Brain Injury-Induced Neurological Damages and Memory Deficits in Rats: Role of BBB Integrity, Microglial Activity, Neuroinflammation, and Oxidative Stress.Mol Neurobiol. 2025 May;62(5):5990-6013. doi: 10.1007/s12035-024-04668-6. Epub 2024 Dec 18. Mol Neurobiol. 2025. PMID: 39692820
-
Long-lasting blood-brain barrier dysfunction and neuroinflammation after traumatic brain injury.Neurobiol Dis. 2020 Nov;145:105080. doi: 10.1016/j.nbd.2020.105080. Epub 2020 Sep 9. Neurobiol Dis. 2020. PMID: 32919030
-
Traumatic Brain Injury and Blood-Brain Barrier (BBB): Underlying Pathophysiological Mechanisms and the Influence of Cigarette Smoking as a Premorbid Condition.Int J Mol Sci. 2020 Apr 14;21(8):2721. doi: 10.3390/ijms21082721. Int J Mol Sci. 2020. PMID: 32295258 Free PMC article. Review.
-
Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury.Neuropharmacology. 2020 Aug 1;172:107907. doi: 10.1016/j.neuropharm.2019.107907. Epub 2019 Dec 6. Neuropharmacology. 2020. PMID: 31837825 Free PMC article. Review.
Cited by
-
Applications of hydrogels and nanoparticles in the treatment of traumatic brain injury.Front Bioeng Biotechnol. 2025 Jan 6;12:1515164. doi: 10.3389/fbioe.2024.1515164. eCollection 2024. Front Bioeng Biotechnol. 2025. PMID: 39834632 Free PMC article. Review.
-
Improving epilepsy management by targeting P2 × 7 receptor with ROS/electric responsive nanomicelles.J Nanobiotechnology. 2025 May 5;23(1):332. doi: 10.1186/s12951-025-03386-y. J Nanobiotechnology. 2025. PMID: 40325469 Free PMC article.
-
Enhancing daily living and cognitive functions in traumatic brain injury patients through Orem's self-care theory.Front Neurol. 2024 Aug 20;15:1449417. doi: 10.3389/fneur.2024.1449417. eCollection 2024. Front Neurol. 2024. PMID: 39228512 Free PMC article.
References
-
- C. L. Eastman, R. D'Ambrosio, T. Ganesh, Neuropharmacology 2020, 172, 107907.
-
- a) N. Ulgen Tekerek, O. Dursun, N. Asilioglu Yener, D. Yildizdas, A. B. Anil, T. Kendirli, A. Koker, S. Karalok, A. Aksoy, E. Kinik Kaya, F. Ekinci, F. Incecik, N. Olgac Dundar, F. Durak, E. Botan, M. Havan, S. Sahin, O. Duman, S. Haspolat, Child's Nerv. Syst. 2023, 39, 3207;
-
- b) S. Ahmed, H. Venigalla, H. M. Mekala, S. Dar, M. Hassan, S. Ayub, Indian J. Psychol. Med. 2017, 39, 114.
-
- a) I. Asikainen, M. Kaste, S. Sarna, Epilepsia 1999, 40, 584;
-
- b) Y. S. Hahn, S. Fuchs, A. M. Flannery, M. J. Barthel, D. G. McLone, Neurosurgery 1988, 22, 864.
MeSH terms
Substances
Grants and funding
- H2023032/Medical Research Project of Jiangsu Commission of Health
- KC21050/Basic Research Program of Xuzhou Department of Science and Technology
- KC23039/Basic Research Program of Xuzhou Department of Science and Technology
- 2021ZA44/Affiliated Hospital of Xuzhou Medical University
- XWKYHT20230005/Xuzhou Municipal Science and Technology Bureau
LinkOut - more resources
Full Text Sources
Medical